Gate2Brain
  • Home
  • Company
  • Team
  • Technology
  • Pipeline-Proof of Concept
  • Investors
  • News & Media
  • Contact
  • Menu Menu

A technology to help treat pediatric cancer

News
Una tecnología para ayudar a tratar el cáncer infantilgate2brain

Una tecnología para ayudar a tratar el cáncer infantil

Expansión. Madrid

. La tecnología de este proyecto de la biotecnológica Gate2Brain, una spin-off del Instituto de Investigación Biomédica (IRB Barcelona), la Universidad de Barcelona y el Institut de Recerca Sant Joan de Déu-Hospital Sant Joan de Déu, nació para cubrir una necesidad no cubierta, mejorar el transporte de fármacos al cerebro.“Existen candidatos a fármaco muy prometedores, pero para el 98% de ellos la existencia de la barrera hematoencefálica es el cuello de botella que dificulta su llegada al cerebro y la capacidad de curar”, afirma Meritxell Teixidó, investigadora del Hospital Sant Joan de Déu-Fundació Sant Joan de Déu y CEO y CSO de Gate2Brain.

Seleccionada por la Fundación La Caixa para recibir ayudas de la convocatoria CaixaResearch Consolidate 2021, esta tecnología representa “una oportunidad para superar esta barrera y llevar estos fármacos hasta el lugar donde deben actuar”, señala Teixidó. “Las farmacéuticas están en plena búsqueda de tecnologías como la nuestra para sus candidatos a fármacos que necesitan una mejora de transporte”, asegura.

Desarrollo

Tras diez tesis doctorales codirigidas, señala, “desarrollamos y patentamos las tres familias de péptidos lanzadera que constituyen la plataforma tecnológica Gate2Brain, que a modo de tractor son capaces de llevar fármacos que, como si fueran remolques, no pueden llegar al sistema nervioso central solos. Durante quince años ha ido creciendo en mi la idea de acompañar la tecnología en su camino al mercado ”

Gate2Brain trabaja en el desarrollo de un péptido lanzadera que puede transportar fármacos

Y destaca como Gate2Brain se creó en julio de 2020 en casa “donde estábamos confinadas, con un núcleo de tres emprendedoras que sueñan ser parte del cambio que nos gustaría ver en el mundo, mejorando la calidad de vida de las personas que sufren una enfermedad del sistema nervioso central y sus familias”.

Fase preclínica

Actualmente, su producto estrella, G2G-002, se encuentra en fase preclínica no regulatoria en animales. “Escogimos como primera indicación un tumor cerebral pediátrico sin cura a día de hoy, que se puede beneficiar de la tecnología Gate2Brain para encontrar una terapia efectiva que llegue mejor al cerebro y luche contra el tumor. Lo estamos haciendo de la mano del Hospital Pediátrico Sant Joan de Déu en Barcelona”, dice la CEO y CSO de Gate2Brain.

Su principal deseo es llegar a las fases clínicas en tres años. “Tenemos por delante tres años intensos para llegar al ensayo clínico. Este será un punto de inflexión para el producto pudiendo entonces licenciarse para que una farmacéutica realice las ultimas etapas hasta el mercado”, afirma Meritxell Teixidó.

A technology to help treat pediatric cancer

Fuente: https://www.expansion.com/empresas.html

May 4, 2022/by noticias
Tags: cáncer infantil, Expansión, Gate2Brain
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on LinkedIn
  • Share by Mail
https://gate2brain.com/wp-content/uploads/2022/05/Diseno-sin-titulo.png 1080 1080 noticias https://gate2brain.com/wp-content/uploads/2020/12/Logo-Gate1Brain500pxGrueso.png noticias2022-05-04 08:13:032022-05-04 09:00:25A technology to help treat pediatric cancer
You might also like
‘Tractor’ proteins that carry drugs to the brain as therapy for incurable pediatric cancer
¿Cómo transportar fármacos al cerebro para tratar patologías?La VanguardiaHow to transport drugs to the brain to treat pathologies?
Gate2Brain abre una ronda puenteo de un millón de euros para ensayos preclínicoPlantaDoceGate2Brain opens one million euro bridge round for preclinical trials
GATE2BRAIN winner of the Barcelona Activa Pre-acceleration competitionBarcelona ActivaGATE2BRAIN WINNER OF THE BARCELONA ACTIVA PRE-ACCELERATION COMPETITION
Within the framework of the discussion-based interview series, Exploration Science, in which scientists talk about their ventures and areas of expertise, our CEO, Dr. Meritxell Teixidó, and the first and only APS American Peptide Idol joined @CEM's Dr. Wendy Hartsock to discuss the work @Gate2Brain is doing in pediatric oncology, dive into the technology, and talk about empathetic leadership and the power of diversity.CEMExploration Science with Dr. Wendy Harsock
2 year anniversaryGate2BrainGate2Brain 2 year highlights at a glance
Foment shows how the leadership of a new generation of female innovators is already a reality at # MWC21Foment del TreballFoment shows how the leadership of a new generation of female innovators is already a reality at # MWC21
Technology closer to young patientsG2BTechnology closer to young patients

CATEGORIES

  • Clipping
  • Events
  • Media
  • News
  • Podcast
  • Press releases
  • Publications
  • Videos

Events

  • The innovative biopharmaceutical industry, a lever for economic and social well-being. A comprehensive approach”, organized by Foment del Treball.Foment del TreballThe innovative biopharmaceutical industry, a lever for economic and social well-being. A comprehensive approach.March 23, 2023 - 08:54
  • G2B at 4YFN 2023G2BGate2Brain at 4YFN-MWC23March 3, 2023 - 08:24
  • Gate2Brain at TransfiereG2BG2B at Transfiere 2023February 17, 2023 - 07:45
  • 📢 On December 13h, Gate2Brain will be participating together with Maribel Berges (AFFIRMA BIOTECH SL), Sven Dr. Mulfinger (Dana_positive maternal health), and Diana Ballart (The Smart Lollipop) in the i4kids Closing Event 2022, sharing achievements and failures of entrepreneurs in #pediatric and maternal #healthcare.i4kidsi4kids Closing Event 2022December 7, 2022 - 12:37
  • WomenStartupAwards, in the "Inspiration" category.WomeninTechSpainFinalist of Women Startup AwardsNovember 15, 2022 - 17:46

SOCIAL

  • linkedin
  • youtube

RSS RSS Ciencia

  • Barcelona to host BIO-Europe Spring 2024 March 23, 2023 biocat
  • 4YFN 2023 sees record turnout, surpassing all expectations March 6, 2023 biocat
  • European health clusters tackle sector’s main challenges in international framework February 24, 2023 biocat
  • Sector experts review main strategic challenges facing BioRegion of Catalonia February 23, 2023 biocat
  • Different health clusters in Ukraine know about the BioRegion thanks to Biocat February 23, 2023 biocat
  • Biocat and Alira Health launch market access program for BioRegion startups February 23, 2023 biocat
  • CRAASH Barcelona celebrates 5th anniversary February 23, 2023 biocat
  • Highlights: New historic record for investment in the BioRegion, new funding, more acquisitions, and ground-breaking research into strokes February 23, 2023 biocat
Gate2Brain

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We use a radically innovative peptide-based patented technology.

Where to find us

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Social

  • linkedin
  • youtube
© Copyright –Edisenius
  • Privacy Policy
  • Legal Notice
  • Cookie Policy
Gate2Brain will be attending The Investment Readiness SeriesGate2Brain will be attending in Basel, Switzerland, the Investment Readiness Series, a @Biocat initiative co-organized by the Delegation of the Government of Catalonia in Switzerland, The aim of the meeting is to put the best projects - from companies and/or research organizations - in contact with investors, business angels, venture capitalists and leading Swiss companies.Within the framework of the discussion-based interview series, Exploration Science, in which scientists talk about their ventures and areas of expertise, our CEO, Dr. Meritxell Teixidó, and the first and only APS American Peptide Idol joined @CEM's Dr. Wendy Hartsock to discuss the work @Gate2Brain is doing in pediatric oncology, dive into the technology, and talk about empathetic leadership and the power of diversity.CEMExploration Science with Dr. Wendy Harsock
Scroll to top
Manage Cookie Consent
This Website uses proprietary and third-party cookies to improve services and facilitate browsing. You can obtain further information about the cookies this site uses and how to limit them in the
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}